Business
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
NE3107-treated patients experienced greater motor control in Parkinson’s trial Patients treated with the combination of NE3107 and levodopa saw improvements
About this update from Biovie Inc.
[{"type":"text","content":"NE3107-treated patients experienced greater motor control in Parkinson’s trial Patients treated with the combination of NE3107 and levodopa saw improvements in their UPDRS Part 3 (motor) score that is 3+ points superior to patients treated with levodopa alone. This level of superiority is considered to be clinically meaningful by Parkinson’s experts. Patients under 70 years of age treated with NE3107/levodopa experienced roughly 6 points superiority compared to those treated with levodopa alone, suggesting that younger patients with less advanced disease progression may experience greater impact from treatment with NE3107.88.9% of patients 30% Improvement at Day 28 vs. Day 0\nSource: BioVie, Inc.","length":990,"tagName":"div"}]